Participated · Seed · Aug 2025

Cascala Health delivers a clinically responsible AI intelligence layer for care teams and post-acute care operators. Its AI-enabled clinical intelligence platform combines AI-powered insights, real-time communication tools, and clinical reasoning, and integrates with any web-based EMR or population health platform to streamline workflows and surface personalized interventions. The company aims to support risk-bearing organizations in delivering better care transitions and ongoing disease management. Cascala has active deployments with early customers, orchestrating care for more than 300,000 patients across thousands of post-acute transitions and empowering over 3,000 primary-care clinicians to engage in patients’ post-acute journeys. Led by CEO and co-founder Matt A. Murphy, the company was launched in mid 2024 and has raised $11.23M to date. The $8.6M seed financing will be used to accelerate product development, expand clinical intelligence capabilities, and grow its customer implementation team.

Participated · Series C · Jan 2025

SafelyYou sells an ambient, AI-powered camera-and-sensor platform that detects when residents might be falling and triggers text and phone alerts to on-call staff. The system does not require wearables and is paired with a remote clinical team that documents falls, reviews videos, conducts root-cause analyses, and issues recommendations. The clinical team has analyzed more than 300,000 on-the-ground events to help reduce future falls. Founder George Netscher says the technology originated in 2015 as part of his doctoral research and the company’s mission is to ensure the highest-quality care for seniors. SafelyYou nearly shut down during the COVID-19 pandemic but survived and now serves nearly 1,000 senior living communities. The company employs roughly 100 people and is San Francisco-based; new capital will support continued expansion. SafelyYou has developed a remote care platform combining real-time AI video technology with a 24/7 remote clinical team to detect and address resident falls. The product is targeted at senior living communities to reduce fall rates and emergency room visits. The company is led by founder and CEO George Netscher and is based in San Francisco, CA. SafelyYou is backed by investors including Eclipse Ventures, Foundation Capital, DCVC, Founders Fund, and Omega Healthcare Investors. The company obtained a $30 million venture loan facility from Horizon Technology Finance, with $10 million initially funded. It intends to use the loan proceeds to expand its business reach. SafelyYou develops an AI-enabled fall management platform that detects falls, analyzes patterns, and pairs technology with professional caregiver intervention to prevent future incidents for seniors and people with Alzheimer’s, dementia, or cognitive impairment. The system combines video review and AI-augmented pattern recognition, reviewing over 1,500 videos of on-the-ground events per month to generate personalized care plans. SafelyYou’s platform is reported to reduce falls by 40% and ER visits from falls by 80%, and a Belmont Village case study found fall-driven ER visits fell to 4% versus an industry average of 17–25%. Beyond detection and prevention, the technology assists caregivers with medication adherence, behavioral monitoring, false-alarm management, memory issues, and occupational therapy support. The company plans to expand availability of its fall-management technology to a wider range of older adults and scale deployments in senior-care facilities. Financially, SafelyYou closed a $30 million Series B in the announced round, bringing its total venture funding to approximately $70 million. SafelyYou offers an AI-enabled fall detection and prevention system specifically designed for memory care and residents with Alzheimer’s disease and related dementias. Its solution uses cameras that only activate when a fall is detected to protect privacy and limit liability. The platform provides post-fall video review to support unwitnessed falls, assist ER decision making, and perform root cause analysis to inform fall prevention. SafelyYou originated in 2015 as the doctoral research of CEO George Netscher at the UC Berkeley Artificial Intelligence Research Lab. The system is already deployed in numerous communities in North America. The company intends to use its new funding to scale its assisted living and skilled nursing business.

Participated · Series B · Apr 2023

Neteera offers a passive, contactless patient monitoring platform that continuously captures vital signs and bio-data without cameras or device manipulation, protecting privacy. Its sensing technology is based on a maintenance-free sub-THz micro-radar on chip that eliminates the need for clothing removal or caregiver presence. The solution is FDA-cleared and targeted at strained healthcare settings and home health. In 2023 the company began selling to a large number of long-term care facilities in the U.S. and reports a significant pipeline of ordered products currently being deployed. Neteera plans to use newly raised funds to expedite production, meet demand for its platform, and recruit installation and deployment personnel. The company is led by CEO Isaac Litman and is based in Jerusalem, Israel. Neteera Technologies is a Jerusalem, Israel–based patient monitoring company led by CEO Isaac Litman. It offers an FDA-cleared continuous, contactless, passive vital-signs and bio-data monitoring solution for strained healthcare settings and home health. The sensing platform eliminates the need for device manipulation, removal of clothing, and caregiver presence. The technology is based on a safe, maintenance-free sub-THz micro-radar on-chip sensor and protects privacy by not using a camera. Neteera closed an approximately $13M Series B and intends to use the funds to accelerate sales, production and deployment of its contactless solution and to further develop features for its proprietary medical sensing platform. The company has also entered a strategic partnership with Omega Healthcare Investors to offer its technology to Omega’s healthcare operating partners.

Participated · Series A · Oct 2022

TSOLife offers an AI-driven resident insight and experience platform (Minerva) that converts resident interviews into structured, actionable data to guide real-time decisions in senior living communities. Its platform captures more than 300 data points per resident and claims a 650% improvement over traditional interview methods, enabling deeply personalized engagement, satisfaction tracking, and sales enablement features. TSOLife reports having gathered social and quality-of-life data for over 125,000 residents and partners with major operators including Benchmark Senior Living, Brookdale Senior Living, Sagora Senior Living, Priority Life Care, Senior Resource Group, Vitality Senior Living, and Commonwealth Senior Living. The company says its work strengthens social drivers of health (connection, purpose, engagement) and can extend residents’ length of stay by more than six weeks. TSOLife plans to use recent growth capital to accelerate product development, enhance its AI capabilities, and expand customer support to operationalize personalization across communities. The platform also includes customizable tools such as inclusivity calendars, digital signage, resident and family apps, satisfaction surveys, and real-time analytics to help communities differentiate to prospects. TSOLife provides an AI-based business intelligence platform called Minerva that creates dashboards and personalized tools for senior living staff. The platform uses artificial intelligence to turn prospect and resident knowledge into actionable insights and to accelerate decision-making. TSOLife partners with senior living communities across the nation to deploy Minerva. The company intends to use the Series A proceeds to accelerate development of the Minerva platform. TSOLife is led by CEO David Sawyer. The financing status and use of funds indicate a focus on product development and scaling adoption within the senior living market.

Participated · Series B · Apr 2021

Theseus Pharmaceuticals is a Boston, MA–based biotechnology company developing pan-variant tyrosine kinase inhibitors designed to anticipate and inhibit new cancer mutations. Its lead candidate, THE-630, is a next-generation pan-variant KIT inhibitor in development for the treatment of refractory GIST. The pipeline also includes a selective EGFR inhibitor intended to overcome C797S-mediated resistance to osimertinib and a third kinase-target program for an undisclosed indication. The company expects to file an IND before the end of the year. Theseus emerged from stealth concurrent with the close of a $100M Series B financing. Leadership includes co-founders William C. Shakespeare, Ph.D. (President of Research and Development) and Iain Dukes, D. Phil. (Interim CEO), and the board now includes representatives from key investors.